Biotech Values

[Titan V]

Celgene Says Juno, Impact Deals Won't Be Its Last
https://www.thestreet.com/story/14463223/1/celgene-not-done-making-deals.html

Following its agreements to buy Juno Therapeutics Inc. (JUNO) and Impact Biomedicines Inc., biopharmaceutical giant Celgene Corp. (CELG) said it continues to have an appetite for deals.

"We will continue to aggressively invest in research and development and to deploy capital to acquire or license the most promising science, technology and products," said Celgene CEO Mark J. Alles on an earnings call on Thursday, Jan. 25.